Randolph's World

A 2024 case report published in Exploratory Research and Hypothesis in Medicine by a clinical team at Kyungpook National University Hospital (Daegu, South Korea) documented three individual patients—one with stage IV metastatic breast cancer, one with recurrent malignant melanoma, and one with castration-resistant prostate cancer—who independently self-administered veterinary-grade fenbendazole after their cancers continued to progress despite surgery, chemotherapy, immunotherapy, and hormonal therapy.

According to the authors, each patient went on to achieve complete or near-complete remission verified by imaging, and all remained disease-free during follow-up periods ranging from 11 months to 34 months, with no fenbendazole-related side effects reported.